The expressions of NF-κB and TGF-β1 in the CS treatment groups were decreased compared with diabetes group (P < 0.05), and the expressions of NF-κB and TGF-β1 were reduced gradually with the increase of CS dose (Figure 3). This evidence concerns the gene TGFB1 and diabetes mellitus.